Avalo Therapeutics AVTX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $25.32M-79.8% | $16.11M-88.0% | $27.26M-66.8% | $42.52M-54.6% | $125.24M+13.5% | ||
| $57.01M— | —— | —— | —— | —— | ||
| $88.83M-30.0% | $105.29M-24.2% | $113.85M+32.2% | $115.19M+20.1% | $126.94M+14.1% | ||
| $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | ||
| $99.89M-27.9% | $116.46M-22.7% | $125.1M+27.1% | $126.58M+16.9% | $138.52M+12.0% | ||
| $356K-47.7% | $137K-51.6% | $474K-73.8% | $2.37M+262% | $681K-25.7% | ||
| $11.6M+107% | $12.94M+85.9% | $7.97M-86.9% | $9.26M-90.4% | $5.62M-97.4% | ||
| $31.57M+98.4% | $33.41M+88.8% | $33.55M-55.7% | $22.01M-80.1% | $15.91M-92.9% | ||
| 200M0.0% | 200M+1,999,900% | 200M0.0% | 200M0.0% | 200M0.0% | ||
| -$468.15M-22.1% | -$448.52M-21.1% | -$434.8M-29.8% | -$404.18M-12.9% | -$383.41M+16.0% | ||
| $68.32M-44.3% | $83.05M-37.6% | $91.55M+334% | $104.57M+868% | $122.62M+209% | ||
| $99.89M-27.9% | $116.46M-22.7% | $125.1M+27.1% | $126.58M+16.9% | $138.52M+12.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Avalo Therapeutics's total assets?
- Avalo Therapeutics (AVTX) holds $99.9M in total assets, down 27.9% year over year.
- How much debt does Avalo Therapeutics have?
- Avalo Therapeutics carries $328.0K in total debt against $68.3M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Avalo Therapeutics have?
- Avalo Therapeutics holds $25.3M in cash and equivalents.
- Can Avalo Therapeutics cover its short-term obligations?
- Its current ratio is 7.66 — current assets exceed current liabilities.
- Where does Avalo Therapeutics's balance sheet data come from?
- Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
